High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases
- PMID: 15252171
- DOI: 10.1093/ndt/gfh307
High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases
Abstract
Background: Pure red-cell aplasia (PRCA) after erythropoietin (Epo) administration due to the appearance of neutralizing anti-Epo antibodies has been reported in over 200 cases between 1998 and 2002. However, large intercountry disparities were observed in the occurrence of this syndrome.
Methods: On behalf of the Swiss Society of Nephrology, a survey was conducted in all the dialysis units of Switzerland in order to collect information on the occurrence, diagnostic and evolution data of the cases observed. A questionnaire was send to the nephrologists in charge of each of the 69 dialysis units in January 2003. The clinical and biological data of the suspected cases were analysed and compared with the data provided to health authorities and pharmaceutical companies.
Results: A total of five cases were identified as true PRCA with demonstrated positive anti-Epo antibodies. They occurred between November 1998 and February 2002, were all treated by haemodialysis and had received Epo subcutaneously. The median appearance time of refractory anaemia after Epo initiation was 10 months (range: 7-54 months). Two cases had been treated exclusively with epoietin-alpha, one solely with epoietin-beta and the two others with a combination of both. With five cases out of a total of about 2500 dialysis patients and 2300 Epo-treated dialysis patients or an exposure rate to Epo of 9900 dialysis patient-years during a 4.3 year period, this prevalence is among the highest of those reported in European countries.
Conclusions: The prevalence of PRCA after Epo administration in dialysis patients appears particularly high in Switzerland. Among the potential explanations, the most plausible are the high percentage of dialysis patients treated with Epo, the almost exclusive subcutaneous administration, the larger market distribution of the epoietin-alpha brand, the eventual disruption of the cold chain and the setting-up of a systematic national survey.
Similar articles
-
Pure red cell aplasia due to treatment with epoietin beta: first case report of PRCA from Poland.Przegl Lek. 2006;63(9):810-4. Przegl Lek. 2006. PMID: 17479877
-
[Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].Rinsho Ketsueki. 2007 May;48(5):391-6. Rinsho Ketsueki. 2007. PMID: 17571584 Japanese.
-
Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.Nephron Clin Pract. 2007;105(2):c90-8. doi: 10.1159/000097889. Epub 2006 Dec 12. Nephron Clin Pract. 2007. PMID: 17164586
-
Pure red cell aplasia secondary to treatment with erythropoietin.J Nephrol. 2003 Jul-Aug;16(4):461-6. J Nephrol. 2003. PMID: 14696747 Review.
-
Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.Curr Med Res Opin. 2004 Jan;20(1):83-6. doi: 10.1185/030079903125002702. Curr Med Res Opin. 2004. PMID: 14741076 Review.
Cited by
-
Epoetin-associated pure red cell aplasia: past, present, and future considerations.Transfusion. 2008 Aug;48(8):1754-62. doi: 10.1111/j.1537-2995.2008.01749.x. Epub 2008 May 14. Transfusion. 2008. PMID: 18482185 Free PMC article. Review.
-
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.Blood. 2005 Nov 15;106(10):3343-7. doi: 10.1182/blood-2005-02-0508. Epub 2005 Aug 11. Blood. 2005. PMID: 16099877 Free PMC article.
-
Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study.Toxins (Basel). 2021 Nov 5;13(11):785. doi: 10.3390/toxins13110785. Toxins (Basel). 2021. PMID: 34822569 Free PMC article.
-
Resistance of dialyzed patients to erythropoietin.Rev Bras Hematol Hemoter. 2015 May-Jun;37(3):190-7. doi: 10.1016/j.bjhh.2015.02.001. Epub 2015 Feb 17. Rev Bras Hematol Hemoter. 2015. PMID: 26041422 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials